Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) have received an average rating of “Buy” from the fourteen brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $22.33.

Several analysts recently commented on the stock. Cowen and Company reiterated a “buy” rating and issued a $19.00 price objective on shares of Cytokinetics, in a research note on Friday, August 4th. HC Wainwright set a $26.00 price objective on shares of Cytokinetics, and gave the company a “buy” rating in a research note on Thursday, August 3rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price objective on shares of Cytokinetics, in a research note on Tuesday, September 26th. Zacks Investment Research upgraded shares of Cytokinetics, from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Monday, August 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Cytokinetics, in a research note on Sunday, September 17th.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/11/13/cytokinetics-incorporated-cytk-given-average-rating-of-buy-by-brokerages.html.

Cytokinetics, (CYTK) remained flat at $$12.55 during mid-day trading on Monday. The company’s stock had a trading volume of 353,900 shares, compared to its average volume of 514,511. Cytokinetics, has a 1 year low of $9.80 and a 1 year high of $17.20. The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14.

Cytokinetics, (NASDAQ:CYTK) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Cytokinetics, had a negative net margin of 172.27% and a negative return on equity of 62.64%. The company had revenue of $6.18 million during the quarter, compared to analysts’ expectations of $5.35 million. equities research analysts expect that Cytokinetics, will post -2.39 earnings per share for the current fiscal year.

In other Cytokinetics, news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics, stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.51, for a total transaction of $67,550.00. Following the completion of the transaction, the chief executive officer now owns 70,180 shares in the company, valued at $948,131.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics, stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total transaction of $55,124.40. Following the transaction, the insider now owns 17,982 shares of the company’s stock, valued at approximately $232,687.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 178,223 shares of company stock valued at $2,639,239. 7.20% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in CYTK. State of Alaska Department of Revenue acquired a new position in Cytokinetics, during the second quarter worth about $109,000. Municipal Employees Retirement System of Michigan purchased a new stake in shares of Cytokinetics, during the second quarter worth about $132,000. Birchview Capital LP purchased a new stake in shares of Cytokinetics, during the third quarter worth about $145,000. BNP Paribas Arbitrage SA grew its holdings in shares of Cytokinetics, by 4,464.4% during the second quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 13,036 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Cytokinetics, by 36.8% during the first quarter. Bank of America Corp DE now owns 12,571 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 3,383 shares in the last quarter. Institutional investors own 71.01% of the company’s stock.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.